Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV) saw a significant decline in short interest in June. As of June 15th, there was short interest totalling 93,200 shares, a decline of 19.0% from the May 31st total of 115,000 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 96,700 shares, the short-interest ratio is currently 1.0 days.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Chilton Investment Co. Inc. bought a new stake in shares of Indivior during the fourth quarter worth $263,000. ADAR1 Capital Management LLC bought a new stake in shares of Indivior during the fourth quarter worth $368,000. Cannon Global Investment Management LLC bought a new stake in shares of Indivior during the first quarter worth $563,000. Campbell & CO Investment Adviser LLC grew its stake in shares of Indivior by 2.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after buying an additional 1,037 shares during the last quarter. Finally, Forsta AP Fonden bought a new stake in shares of Indivior during the first quarter worth $641,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on shares of Indivior in a research report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price target for the company.

Indivior Price Performance

INDV traded down $0.48 during trading on Tuesday, hitting $15.27. 118,459 shares of the stock traded hands, compared to its average volume of 110,411. Indivior has a twelve month low of $14.38 and a twelve month high of $24.90. The company has a market cap of $2.11 billion, a price-to-earnings ratio of 1,531.00 and a beta of 0.69. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.92 and a quick ratio of 0.74. The business has a 50 day moving average price of $17.25 and a 200 day moving average price of $18.09.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.01). Indivior had a net margin of 0.44% and a return on equity of 842.72%. The firm had revenue of $284.00 million for the quarter, compared to analyst estimates of $300.00 million. Equities research analysts forecast that Indivior will post 2 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.